

























Journal of the American College of Cardiology Vol. 56, No. 9, 2010
© 2010 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00
PSTATE-OF-THE-ART PAPER
Stroke Prevention and Treatment
James D. Marsh, MD,* Salah G. Keyrouz, MD†
Little Rock, Arkansas
The decline in stroke incidence and mortality in the U.S. over the past 20 years is reaching a plateau, and the
number of strokes may actually start to increase as the population ages. However, recent clinical trials have
demonstrated that there are numerous opportunities to improve stroke prevention strategies and also opportuni-
ties to effectively intervene in and treat acute strokes. For patients with diabetes and for those with prior strokes
or transient ischemic attacks, it has become evident that aggressive low-density lipoprotein lowering with statin
medications will decrease the risk for total and fatal strokes. Optimal anticoagulation and antiplatelet therapy
for primary and secondary stroke prevention in atrial fibrillation is being carefully defined. With numerous novel
factor Xa and direct thrombin inhibitor drugs completing phase III clinical trials, it is likely that additional oral
anticoagulant drugs will be clinically available for stroke prevention soon. Additionally, a major clinical trial is
nearing completion that may resolve the role of carotid stenting and carotid endarterectomy in primary and sec-
ondary stroke prevention. There are recent notable advances in the acute treatment of stroke. It is likely that the
time window for thrombolysis for appropriate patients with strokes will be increased from 3 to 4.5 h, permitting
the inclusion of more patients in this treatment approach. There is ongoing investigation of intra-arterial throm-
bolysis and of acute intra-arterial thrombus extraction for treatment of selected patients with strokes. Unlike the
progress in treatment of ischemic strokes, treatment of hemorrhagic stroke is progressing more slowly. (J Am
Coll Cardiol 2010;56:683–91) © 2010 by the American College of Cardiology Foundation


























erebrovascular disease is the third leading cause of death in
he U.S. and the number 1 cause of long-term major
isability. It is estimated that there are 795,000 incident
trokes in the U.S. each year, resulting in 1 of every 17
eaths in the U.S. due to stroke. There are more than 4.8
illion stroke survivors alive today (1). Although there was
60% decline in stroke mortality over the 29-year period
etween 1968 and 1996, the rate of decline began to slow in
he 1990s and has plateaued in several regions of the
ountry. There are major regional differences in stroke
ncidence across the U.S. (Fig. 1) (1), with the persistence
ver many decades of a high-incidence “stroke belt” cen-
ered on southeastern and south central states.
In considering stroke prevention, one must be aware that
he mechanisms of disease underlying the clinical stroke
yndrome are quite varied, and thus preventive measures
ust be tailored to the disease mechanism. Overall, 87% of
trokes are ischemic, 9% are due to intracerebral hemor-
hage (ICH), and 4% are due to subarachnoid hemorrhage
2). Among all strokes in 1 series (3), about 19% were
ardioembolic, 26% were lacunar, 15% were due to carotid
rom the *Department of Internal Medicine, University of Arkansas for Medical
ciences, Little Rock, Arkansas; and the †Department of Neurology, University of
rkansas for Medical Sciences, Little Rock, Arkansas. The authors have reported that
hey have no relationships to disclose.p
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009, accepted December 7, 2009.isease, and about 36% remained cryptogenic (no definite
ause identified) (Fig. 2). Stroke subtype is somewhat
ependent on ethnicity (3).
therosclerosis and stroke prevention. Atherosclerosis is
systemic disease affecting the large and medium-sized
rteries of the entire systemic arterial tree. Therefore,
easures to prevent atherosclerosis systemically will affect
isk for both ischemic stroke and ischemic heart disease.
isk factors for atherosclerosis and ischemic stroke include
moking, hypertension, diabetes, and elevated cholesterol.
here is very compelling evidence from clinical trials of
holesterol lowering for ischemic heart disease indicating
hat risk for the first stroke is markedly diminished with
harmacological lowering of low-density lipoprotein (LDL)
nd total cholesterol (4). Statin therapy reduces LDL
holesterol level, with each 10% reduction in LDL choles-
erol estimated to decrease the risk for stroke by 15% (4).
or patients with established coronary artery disease, there
s now compelling evidence that statins reduce the risk for
troke compared with placebo (5,6). Reviewed elsewhere are
host of additional trials of statin therapy for patients with
stablished ischemic heart disease that demonstrated a
ubstantial decrease in stroke risk (7).
Diabetes is a major risk factor for stroke. An important
tudy, the CARDS (Collaborative Atorvastatin Diabetes
tudy), randomized patients with diabetes and 1 additional
isk factor to placebo or atorvastatin. In this study of 2,838
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statin compared with placebo (8).
The benefit of statins for stroke
prevention in patients with dia-
betes is very clear. In 2006, the
American Heart Association rec-
ommended that adults with dia-
betes, particularly those with
other atherosclerosis risk factors,
be treated with statins (9). The
optimal aggressiveness for glyce-
mic control remains controver-
sial. Some recent evidence sug-
gests tight glycemic control in
patients with ischemic cardiovas-
cular disease actually worsens
outcomes (10), and other evi-
dence favors moderately aggres-
sive glycemic control.
The prevention of recurrent
strokes has focused on the use of
antiplatelet therapy and blood
pressure control; the role of LDL
lowering for secondary stroke
prevention had been unclear un-
til recently. To address the im-
portant question of the potential
role of LDL lowering with statin
therapy for secondary prevention
fter a stroke or transient ischemic attack (TIA), the
PARCL (Stroke Prevention by Aggressive Reduction in
holesterol Levels) study was undertaken (11). In this
tudy, 4,731 patients with prior strokes or TIAs, but no
vident ischemic heart disease and no atrial fibrillation
AF), were randomized to placebo or atorvastatin 80 mg/
ay. During the median follow-up period of nearly 5 years,
here was a 16% risk reduction with atorvastatin treatment
Abbreviations
and Acronyms
AF  atrial fibrillation




CI  confidence interval










OR  odds ratio
PFO  patent foramen
ovale
TIA  transient ischemic
attack




Figure 1 Stroke Age-Adjusted Death Rates by State, 2005
Reprinted, with permission, from Lloyd-Jones et al. (1).or fatal or nonfatal stroke (p  0.03) and a 23% reduction
n risk for TIA or stroke (p  0.001). There was also a
eduction in coronary events (hazard ratio: 0.58; p  0.001)
n this population with no known ischemic heart disease at
ime of enrollment in the study. Thus, the evidence is
ompelling that for secondary stroke prevention, high-dose
tatin therapy with atorvastatin reduces the risk for recurrent
troke and TIA and also markedly decreases the risk for
cute coronary events. Low high-density lipoprotein is an
ndependent risk factor for stroke, and recent evidence
ndicates that adding a high-density lipoprotein–raising
rug (niacin) to a statin improves a surrogate measure
carotid intima-media thickness) for atherosclerotic disease
12).
arotid endarterectomy (CEA) and carotid artery stenting
CAS). CEA. Two seminal studies, NASCET (North
merican Symptomatic Carotid Endarterectomy Trial) and
CST (European Carotid Surgery Trial), examined the
otential benefit of CEA in patients with symptomatic
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August 24, 2010:683–91 Stroke Prevention and Treatmentarotid stenosis. For symptomatic subjects, CEA benefitted
hose with 50% to 99% stenoses, reviewed by Chaturvedi et
l. (13). The landmark ACAS (Asymptomatic Carotid
therosclerosis Study) established that for patients with
0% to 99% stenosis who could be operated on with very
ow perioperative risk for stroke or death, CEA produced
ore favorable outcomes than best medical therapy (relative
isk reduction: 53%, p  0.004). (14). Thus, the current
ecommendation is that for symptomatic patients with a
5-year life expectancy and 50% to 99% stenoses, CEA
hould be considered. Additionally, for asymptomatic pa-
ients with a 5-year life expectancy and 60% to 99%
tenosis, it is reasonable to consider CEA (13,15). Of note,
here is good evidence that patients with more severe
tenoses (but not subtotal or total occlusions) are more likely
o benefit from CEA than those with less severe stenoses
13,15).
AS. Recently completed and ongoing clinical trials are
omparing CAS with CEA for patients with symptomatic
nd asymptomatic carotid artery stenosis. At this time, there
re major unanswered questions regarding the potential
uperiority of CAS compared with CEA for various patient
roups with regard to safety, efficacy, rate of recurrent
tenosis, and durability of clinical benefit. A recent trial
tudied high-risk patients (16). The investigators concluded
hat CAS was not inferior to CEA. However, it has become
vident that the relative safety of CEA compared with CAS
s critically dependent on the skill and qualifications of the
perator (17). In 1 European study in which there was not
igorous prequalification of CAS operators, the 30-day
troke or death rate was high (9.6%) and inferior to that
ith CEA (17). The 30-day ipsilateral stroke or death rates
or CEA and CAS were also compared in the SPACE
Stent-Protected Angioplasty Versus Carotid Endarterec-
omy) trial. With a CEA end point rate of 6.34% and a
AS end point rate of 6.84%, noninferiority of CAS was
ot established (18). Longer-term follow-up data are
waited. A recent subgroup analysis from the trial suggests
hat CAS may be safer in younger patients, while a
ifference in outcomes for CEA and CAS was not evident
n older patients (19).
A major U.S. and Canadian trial comparing the safety,
fficacy, and durability of CAS with those of CEA in
ymptomatic and asymptomatic patients is nearing conclu-
ion. The CREST (Carotid Revascularization Endarterec-
omy vs. Stenting Trial) enrolled 2,522 patients with symp-
omatic and asymptomatic carotid stenoses. The primary
nd points are death, stroke, and myocardial infarction
uring the first 30 days after the procedure and then
psilateral stroke during the year after the procedure. The
REST investigators undertook a rigorous credentialing
rocess for both the CEA surgeons and CAS operators. A
arge lead-in study for CAS was performed, and initial
esults show that the process of careful qualification of the
perators results in 30-day death or stroke rates of 4.5% for pomen and 4.2% for men (p  NS) (20). Until the results
f CREST are available, there are insufficient data to make
firm judgment on the superiority of CEA compared with
AS, particularly which patient groups may benefit from 1
pproach or the other.
ardioembolic strokes. AF. In patients with paroxysmal,
ersistent, or permanent AF, anticoagulant and antiplatelet
herapy unequivocally decreases stroke risk. The SPAF
Stroke Prevention in Atrial Fibrillation) study (21,22) and
dditional landmark studies have clearly established the
oles of warfarin and aspirin for stroke prevention (9). Over
5 years of intense investigation, it has become evident that
here are low-, intermediate-, and high-risk groups for
troke in AF that can be categorized by the CHADS2 score
23); antithrombotic therapy can be tailored to the risk
ategory, as reviewed by Fuster et al. (24). If there are no
isk factors, the recommended therapy is aspirin 81 to 325
g/day. Moderate-risk factors include age 75 years,
iabetes, hypertension, heart failure, and ejection fraction
35%. For 1 moderate-risk factor, the recommendation is
spirin 81 to 325 mg/day or warfarin (target international
ormalized ratio [INR] 2.0 to 3.0). For any high-risk factor
prior stroke or TIA) or more than 1 moderate-risk factor,
arfarin (target INR 2.0 to 3.0) is recommended.
The actual prevalence of paroxysmal AF in the U.S. is
nknown, but because of the aging population and higher
ncidence of AF in older patients, it is very likely that the
revalence of paroxysmal AF is increasing. Moreover, con-
emporary pacemakers and intracardiac defibrillators usually
ave the capacity to record high-rate episodes that are AF or
trial tachycardia, and interrogation of devices is demon-
trating considerably more paroxysmal AF than anticipated.
ndexes of AF and atrial tachycardia are being developed,
nd the AF or atrial tachycardia burden (h/day) is being
nvestigated as a risk factor for thromboembolism and
troke.
Warfarin has numerous well-known limitations in its use.
here are currently at least 9 drugs in phase II and III
linical trials as possible substitutes for warfarin. A pivotal
rial comparing warfarin with dabigatran, a direct thrombin
nhibitor for stroke prevention, was recently reported (25).
he exciting findings established that dabigatran is more
fficacious at a dose of 150 mg twice daily, has similar safety
o warfarin, and is much easier to administer. No monitor-
ng of INR is needed, and there appear to be fewer drug and
ood interactions. It is likely that this trial with dabigatran,
f approved by the U.S. Food and Drug Administration
FDA), will lead to the use of dabigatran rather than
arfarin for a large number of patients with AF.
Novel antiplatelet strategies for stroke prevention have
een investigated in patients who are not candidates for
arfarin therapy, often because of perceived risk for bleed-
ng or falls. The ACTIVE A (Atrial Fibrillation Clopi-
ogrel Trial With Irbesartan for Prevention of Vascular
vents) evaluated the role of clopidogrel plus aspirin for the
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Stroke Prevention and Treatment August 24, 2010:683–91lopidogrel 75 mg/day plus aspirin 75 to 100 mg/day
ecreased the risk for stroke (2.4% per year) compared
ith aspirin alone (3.3% per year) (p  0.001). Major
leeding increased in the clopidogrel-plus-aspirin group
2.0% per year) compared with aspirin alone (1.3% per
ear) (p  0.001).
In another arm of ACTIVE, the ACTIVE W, patients
ith AF and at least 1 risk factor who were candidates for
arfarin therapy were randomized to either warfarin (target
NR 2.0 to 3.0) or clopidogrel 75 mg/day plus aspirin 75
o 100 mg/day. The trial was stopped early because of
lear superiority of oral anticoagulation therapy (27).
hus, for warfarin-eligible patients, the regimen of aspi-
in plus clopidogrel produces inferior outcome and can-
ot be recommended.
EFT VENTRICULAR THROMBI AS A SOURCE OF CARDIO-
MBOLIC STROKE. There is little doubt that after acute
yocardial infarction and in chronic left heart failure, mural
hrombi may form and produce an embolic stroke. How-
ver, for patients in sinus rhythm, the optimal strategy to
revent left ventricular thrombi from forming and emboli-
ing is uncertain. To determine whether warfarin, clopi-
ogrel, or aspirin would have an optimal effect on outcome
n chronic heart failure, including an effect on stroke
revention, Massie et al. (28) launched the WATCH
Warfarin and Antiplatelet Therapy in Chronic Heart
ailure) trial. Unfortunately, because of slow enrollment,
he trial was terminated early, with only 1,587 patients
nstead of the planned 4,500. The study was underpowered,
ut the investigators concluded that for the primary com-
osite end point and all-cause mortality, major differences
etween outcomes with warfarin and antiplatelet therapy are
nlikely. It cannot be considered a definitive trial.
A major trial, WARCEF (Warfarin Versus Aspirin in
atients With Reduced Cardiac Ejection Fraction), is under
ay to compare aspirin and warfarin to prevent stroke and
eath for patients with left ventricular ejection fractions
35% (29). This study will provide definitive evidence for
he relative efficacy of warfarin or aspirin for patients with
ow ejection fractions who are in sinus rhythm. The
ARCEF trial was projected to successfully complete
ecruiting in February 2010, with publication of the primary
ndings in 2012. Until the results of the trial are published,
here are no definitive data from which to draw conclusions
egarding optimal antithrombotic therapy for stroke preven-
ion in patients with low ejection fractions.
therosclerotic disease of the ascending aorta and aortic
rch and risk for ischemic stroke. It has been long
uspected that atherosclerotic plaques in the aortic arch are
ssociated with ischemic strokes (30). Plaques 4 mm in
hickness as determined by transesophageal echocardiogra-
hy appear to be particularly strongly associated with brain
nfarct in patients who present with strokes (30). Causality
as been more difficult to establish. Furthermore, the
ssociation between proximal aortic plaques and stroke in ehe general population has been unclear. In 1 population-
ased study (31), after adjustment for risk factors, large
ortic arch plaques were not associated with combined
ascular events. Associated cofactors, notably hyperlipid-
mia, may be the underlying cause for the previously
escribed association between plaque and stroke.
atent foramen ovale (PFO) and stroke prevention. Ap-
roximately 25% to 40% of strokes are cryptogenic (32).
he association between a PFO and cryptogenic stroke is
ell established (33). Numerous studies reviewed elsewhere
ndicate that associated factors, including the size of the
FO, the size of the interatrial shunt, and the presence of an
trial septal aneurysm, may all contribute to the relative risk
or a stroke (32,34,35). The optimal management of pa-
ients with PFOs and TIAs or strokes remains controversial.
t appears that for medical management, aspirin is as
ffective as warfarin in secondary prevention (36).
Surgical closure of PFOs has been undertaken in the past
32), but the surgical approach is no longer widely used
ecause of the growth of catheter-based minimally invasive
pproaches. There have been numerous studies, some ran-
omized and some observational, using catheter-delivered
evices to close PFOs. Indeed, there are currently 16 active
rials of strategies for PFO management, mostly for isch-
mic stroke indications.
The American Heart Association/American Stroke As-
ociation guidelines recommend antiplatelet therapy for
atients with TIAs or strokes, unless there are additional
ndications for warfarin therapy (9). The guidelines for
econdary stroke prevention state that “insufficient data exist
o make a recommendation about PFO closure in patients
ith a first stroke and PFO. However, PFO closure may be
onsidered for patients with recurrent cryptogenic stroke
espite optimal medical therapy. There is a major need for
efinitive resolution of the optimal management of patients
ith a documented PFO and who have had an initial stroke
r TIA.” Physicians are urged to enroll suitable patients in
he ongoing randomized trials to resolve this question (34).
ypertension and stroke. For more than 30 years, the
vidence has been compelling that there is a strong associ-
tion between elevated blood pressure and stroke, both
schemic stroke and ICH. The relationship between blood
ressure and stroke is a continuous variable and independent
f other risk factors (15). The relationship between hyper-
ension and lacunar stroke is particularly strong and may
ccur in individuals with no other stroke risk factors. It
as become abundantly clear that screening for hyperten-
ion and treatment of hypertension are important and
ffective in stroke prevention. Numerous classes of anti-
ypertensive medications, including thiazide diuretic
gents, angiotensin-converting enzyme inhibitors, angio-
ensin receptor blockers, beta-blockers, and calcium-
hannel blockers, have all been shown to decrease the risk
or cardiovascular events including stroke. There may be a
articular advantage to the use of angiotensin-converting
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August 24, 2010:683–91 Stroke Prevention and Treatmenttroke prevention (37,38). It is a Class IA recommendation
f the AHA and American Stroke Association Stroke
ouncil that hypertension be diagnosed and treated to
revent stroke.
revention of ICH. Prospective, community-based stud-
es have clearly established that hypertension is the leading
ontrollable risk factor for hemorrhagic stroke in the U.S.
opulation (39–41). Age and African American ancestry
ere associated with ICH and affected both sexes equally
2). Smoking is also a substantial risk factor for both sexes
42,43).
ifestyle and stroke prevention. For many years, it has
een well established that lifestyle contributes to the risk for
yocardial infarction. However, only recently has the major
ffect of lifestyle on stroke risk been established. Chiuve et
l. (44) conducted a major cohort study of over 114,000 men
nd women and identified diet and lifestyle factors with an
mportant bearing on lowering stroke risk. The 5 factors are
ody mass index 25 kg/m2, 30 min/day of moderate
ctivity, not smoking, modest alcohol intake, and scoring in
he top 40% on a healthy diet score. For women, 54% of
schemic stroke risk is attributable to lack of adherence to
ow-risk lifestyle. For men, 52% of ischemic strokes may
ave been prevented. Thus, for both men and women, a
ealthy lifestyle has an immense impact on stroke risk. It
learly must be the cornerstone of all physician recommen-
ations for stroke prevention.
troke Treatment
yperacute and acute therapy for ischemic stroke. The
rogress in the past 15 years in the treatment of ischemic
troke exceeds anything seen in other neurological con-
itions. We have also witnessed the establishment of
ertified stroke centers, in which a systematic and orga-
ized approach with standard-of-care measures is at the
ore of investigations and treatment of stroke patients.
espite these efforts, stroke victims are still missing out
n timely therapy, in part because they are poorly informed
ut also because of the small window of opportunity for
ntervention.
NTRAVENOUS (IV) THROMBOLYSIS. IV thrombolysis with
issue plasminogen activator (t-PA) remains the only FDA-
pproved acute therapy for ischemic stroke. This major
reakthrough occurred in 1996, when t-PA was approved
or ischemic stroke within 3 h of symptom onset (45). IV
-PA significantly improved outcomes after ischemic stroke
t 3 months; the odds ratio (OR) for a favorable outcome
as 1.7 (95% confidence interval [CI]: 1.2 to 2.6; p 
.008). Mortality at 3 months was similar in the 2 groups.
he incidence of symptomatic ICH within 36 h after the
nset of symptoms was significantly higher in the IV t-PA
roup (6.4 vs. 0.6, p  0.001). This explains in part the
eluctance of some physicians to administer IV t-PA.
wenty percent to 25% of patients with strokes arrive at the
ospital within 3 h of symptom onset, but currently, ohrombolysis is used only in a small fraction of these patients
46). A recent study, the ECASS III (European Coopera-
ive Acute Stroke Study) showed that the window for
ntervention could be extended up to 4.5 h (47). This trial
xcluded patients with severe stroke (National Institutes of
ealth Stroke Scale score 25) and those with diabetes
ho had previous strokes. More patients had favorable
utcomes, as assessed by a modified Rankin Scale score of 0
r 1, with IV t-PA than with placebo (52.4% vs. 45.2%;
R: 1.34; 95% CI: 1.02 to 1.76; p  0.04). The incidence
f symptomatic ICH was higher in the IV t-PA group than
he placebo group (2.4% vs. 0.2%, p  0.008). The death
ate did not differ between the 2 groups.
Currently in Europe, IV thrombolysis is performed up to
.5 h from the time of symptom onset. The FDA has not
et approved the use of IV t-PA between 3 and 4.5 h in the
.S. Nonetheless, many stroke centers have updated their
reatment algorithms with the new time frame, a practice
hat has been recently recommended by the American Heart
ssociation (48). The earlier IV thrombolysis is performed,
he more likely it is to be efficacious; therefore, practitioners
hould make every effort to administer t-PA soon after
ymptom onset within the window of opportunity (45).
Many investigators have sought augmentation of throm-
olytic effect by combining other therapeutic modalities to
hrombolysis; however, thus far, no such combination ther-
py has affected overall outcomes (49).
NTRA-ARTERIAL (IA) THROMBOLYSIS. Two landmark
tudies investigated IA thrombolysis in patients with middle
erebral artery territory strokes and M1 or M2 occlusion
ithin 6 h of symptom onset. The PROACT (Prolyse in
cute Cerebral Thromboembolism) and PROACT II trials
ppeared promising but were not definitive, and the therapy
IA prourokinase) did not receive FDA approval (50,51).
owever, many stroke centers are currently offering IA
hrombolysis to patients, either alone or in combination
ith IV t-PA. The IMS (Interventional Management of
troke) study explored this latter approach because investi-
ators noted the relative lack of efficacy of IV t-PA on large
trokes and patients with major arterial occlusions; there are
everal ongoing investigations (52,53).
ECHANICAL THROMBECTOMY. Several devices for embo-
ectomy are being studied, including the FDA-approved
erci device (Concentric Medical, Inc, Mountain View,
alifornia) in the MERCI (Mechanical Embolus Removal
n Cerebral Ischemia) trial (54). The Multi MERCI trial
urther investigated the role of the Merci device in patients
ith acute ischemic strokes within 8 h of symptom onset
55). It is important to note, however, that the efficacy of the
erci device was evaluated against historical controls of IV
nd IA t-PA and not evaluated in a randomized controlled
rial. Unlike its sister trial, the Multi MERCI trial allowed
echanical embolectomy to be performed on patients who
ad already received IV t-PA and had persistent large vessel
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Stroke Prevention and Treatment August 24, 2010:683–91atients in whom mechanical intervention failed to achieve
rterial patency (at least Thrombolysis In Myocardial In-
arction flow grade 2). Recanalization was achieved in
5% of 164 patients in whom the device was deployed
nd in 68% of the same cohort when adjuvant IA
hrombolysis was used. Symptomatic ICH occurred in
.8% of patients. When recanalization occurred, good
eurological outcomes at 90 days were observed in 49% of
atients compared with 9.6% of patients who did not
ecanalize (p  0.001). Similarly, in the same groups,
0-day mortality was observed in 25% and 52%, respectively
p  0.001). Mechanical thrombectomy remains an area of
ctive clinical investigation.
yperacute and acute therapy for ICH. The mortality
nd morbidity of ICH is staggeringly high. ICHs account
or 9% to 15% of all strokes, affecting 70,000 Americans
early (56), yet they are responsible for a disproportionate
eath rate approaching 50% (57). Determinants of outcome
nclude age, baseline hematoma volume, admission Glasgow
oma Scale score, presence and amount of intraventricular
lood, and early hematoma growth (57–59). One-half of
eaths from ICH occur in the first 48 h after bleeding, as a
esult of mass effect and brain tissue shifts. The latter are
ntimately related to hematoma volume (57). Perihemato-
al edema and inflammation linked to thrombin and iron
oxicity add to the acute, cataclysmic neurological injury in
atients with ICHs (60). Most of the remaining deaths
ccur later, within the first 30 days, as a consequence of
edical complications made more likely due largely to the
unctional disability (61). Unlike the breakthrough achieved
n the treatment of ischemic stroke during the past 2
Figure 3 A Left Hypertensive Thalamic Hemorrhage
A left hypertensive thalamic hemorrhage (4 ml) 3 h after symptom onset (left) and
Hematoma expansion in this case, ultimately lethal, was accompanied by clear neecades, progress has been limited in the treatment of ICH. aOWERING OF ACUTELY ELEVATED BLOOD PRESSURE.
hronic hypertension is a major risk factor for developing
CH, and aggressive antihypertensive therapy unequivocally
owers the risk for ICH (62). In the acute phase of ICH,
levated blood pressure is commonly encountered, with
vidence linking acute hypertension to increased mortality,
isability, and risk for hematoma growth (63). One argu-
ent against aggressive treatment of acute hypertension in
CH was altering autoregulation and potentially reducing
erfusion around the hematoma. However, several investi-
ations suggest that more aggressive lowering of blood
ressure may be safe (64–66); nonetheless, definitive data
re still awaited to shed more light on this most important
linical dilemma.
EMOSTATIC THERAPY. Although bleeding into brain pa-
enchyma is apoplectic, with hematoma reaching its maxi-
um volume within minutes, this process is far from being
tatic. Early hematoma growth or expansion (defined as a
33% or 12.5-ml increase in the size of the clot during the
rst 24 h) has been shown to occur (Fig. 3). In 1 study of
ead computed tomography in 204 patients with ICH who
ad repeat computed tomography within 48 and 120 h from
he onset of bleeding, 20% of patients developed hematoma
xpansion. Those were more likely to deteriorate clinically
han patients who did not experience expansion (OR: 11.7;
5% CI: 5.0 to 27.8). Furthermore, 29% of patients with
xpansion died early after bleeding, in contrast to 3% of
atients who did not have expansion (67). Other investiga-
ors have reported concordant findings (68).
In light of these observations, and especially after the
ailure of surgical evacuation to improve outcomes of pa-
ients with ICH (see the following discussion), an interest in
ter (16 ml) (right).
ical deterioration.1 h la
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August 24, 2010:683–91 Stroke Prevention and Treatmentncidence of hematoma expansion and therefore clinical
eterioration emerged (69). Given its characteristics as a
emostatic agent (enhancing coagulation and stopping
leeding), recombinant factor VIIa, the activated form of
he naturally occurring factor VII, was studied in patients
ith ICH. In pharmacological doses and through a cascade
f molecular activation, recombinant factor VIIa results in a
thrombin burst” generated by activated platelets. Despite
nitial encouraging results, a pivotal trial of this strategy did
ot show improvement in outcomes (70–72). There is
otential for recombinant factor VIIa use in warfarin-
elated ICH and less devastated patients with smaller
emorrhages and more favorable baseline examination
esults.
URGICAL EVACUATION. The rationale for the evacuation
f cerebral parenchymal hemorrhages is to rid neurons and
lial cells from the source of thrombin and iron, both toxic
ompounds implicated in edema formation and secondary
amage to brain tissue not yet damaged by the initial
hysical insult that occurs when bleeding takes place. In
ddition, the surgical removal of blood clots may alleviate
ressure gradients inside the skull and restore normal
natomy. This would then lessen or abolish altogether
ressure on, and injury to, vital midline diencephalic struc-
ures that could subsequently lead to brain death.
McKissock et al. (73) conducted an early trial of hema-
oma evacuation in spontaneous ICH. It demonstrated a
rend toward worse outcomes with surgical intervention.
ubsequently, many studies using different techniques of
lot evacuation were published. Most are very small, failing
o show any statistically significant and consistent benefit of
urgery over conservative medical management (74,75).
ne trial, the STICH (International Surgical Trial in
ntracerebral Haemorrhage), is notable (76). It is the largest
o date and most recent completed randomized trial of the
urgical evacuation of spontaneous ICH. It is a multicenter
rial of different surgical techniques for early (within 24 h of
andomization) hematoma evacuation versus conservative
edical management. Using the extended Glasgow Coma
cale at 6 months as an end point, favorable outcomes were
bserved in 26% of patients allocated to the early surgery
rm, compared with 24% of patients allocated to conserva-
ive treatment (OR: 0.89; 95% CI: 0.66 to 1.19). Further-
ore, the mortality rate in the early surgery group was 36%
ompared with 37% for the conservative treatment group
OR: 0.95; 95% CI: 0.73 to 1.23; p  0.707). Subgroup
nalyses showed a potential benefit for surgery in patients
ith superficial hematoma. This latter finding served as the
asis for the ongoing STICH II trial, which is comparing
arly surgery with conservative treatment in patients with
obar hematoma. In current clinical practice, ICHs are
arely evacuated unless they are lobar.
ARFARIN-RELATED INTRACEREBRAL HEMORRHAGE
WRICH). This dreaded complication of warfarin therapy is
elatively common in clinical practice. The annual risk for aRICH is 0.6% to 2% (77). WRICH has a worse
rognosis compared with non-WRICH (78), partly because
t afflicts older patients and has larger initial hematoma
olumes (79), which are not only more likely to expand but
ould do so beyond the 24-h period during which expansion
s expected (78).
There are no available clinical trials gauging the effec-
iveness of different acute therapies for WRICH. It is
ommon practice to discontinue warfarin and correct the
NR with the quick administration of vitamin K (IV or
arenteral) and fresh-frozen plasma. There is much current
nterest in prothrombin complex concentrate, given how
uickly it normalizes the INR, and the small administration
olume compared with fresh-frozen plasma.
ikely Developments in the Next 5 Years
t is very likely that alternatives to warfarin for oral antico-
gulation in AF will be introduced into clinical practice
oon. Dabigatran appears to be a promising orally effective
irect thrombin inhibitor that may achieve FDA approval
oon (25). No doubt, newer antithrombotic agents will
resent some clinical challenges to use, including bleeding.
The role of CAS relative to CEA will become clearer as
he CREST trial results are published in 2010. Also as the
ARCEF trial is concluded and published in 2011 and
012, the role of aspirin compared with warfarin for stroke
revention in patients with low left ventricular ejection
ractions will become clear.
Mechanical embolectomy is undergoing further investi-
ations in 2 ongoing studies: the IMS III trial and the MR
ESCUE (Magnetic Resonance and Recanalization of
troke Clots Using Embolectomy) trial. Imaging (magnetic
esonance imaging and angiography) is being used to better
dentify eligible patients. In expert hands, mechanical clot
etrieval alone or in combination with other therapeutic
odalities is appealing because it extends the window of
pportunity for treatment, a major hurdle for effective acute
troke treatment delivery. The results of IMS III and MR
ESCUE are eagerly awaited.
Finally, the FDA will likely endorse extension of the time
indow for IV t-PA administration to 4.5 h for selected
atients in the U.S.
Demographic factors (age and obesity, with resultant
omorbidities) will tend to increase stroke risk over the next
0 years in the U.S. However, there is reason for a cautious
ptimism that relatively new and specific strategies for
troke prevention and treatment will be countervailing and
ecrease stroke incidence and morbidity.
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